Orchid Chemicals & Pharmaceuticals Limited

Merck Sharp + Dohme Corp.

Orchid Pharma Ltd.

Allecra Therapeutics Gmbh

Gopalan Balasubramanian

Shridhar Narayanan

Venkatesan Parameswaran

Sanjeev Saxena

Maneesh Paul-Satyaseela

Sukunath Narayanan

Ganapavarapu Veera Raghava Sharma

Santosh Vishwakarma

Hariharan Periasamy

Ravi P Nargund

Sriram K Rajagopal

Michael W Miller

Sheo B Singh

Ravikumar Tadiparthi

Shuzhi Dong

Sukumar Sakamuri

Katherine Young

Hongwu Wang

Senthilkumar Udayampalayam Palanisamy

Virendra Kachhadia

Uma Ramachandran

Sridharan Rajagopal

Durairaj Peter Bhakiaraj

Venkatesan Janarthanam

Sathya Narayana Thara

Maruthikumar Narayanam

Sathyanarayana Gadde

Sivanesan Dharmalingam

Franklin Pooppady Xavier

Jeyamurugan Mookkan

Jeganatha Sivakumar Balasubramanian

Agneeswari Rajalingam

Jayanarayan Kulathingal

Bharani Thirunavukkarasu

Visweswara Akella Satya Surya Srinivas

Thirunavukkarasu Sappanimuthu

Aravind Appu

Kilambi Narasimhan

Prabhakar Rao Gunturu

Senthilnathan Manickam

Om Reddy Gaddam

Chidambaram Venkateswaran Srinivasan

Manjula Devi Deshkumar

Ganapavarapu Sharma

Narayanan Surendran

Lolaknath Santosh Vishwakarma

Venkateshwarlu Jakkala

Gajendra Singh

Michael Wayne Miller

Sridhar Ramanathan Iyer

Lavanya Andiappan

Saravanan Thirunavukkarasu

Sheo Singh

Michael Miller

Surendran Narayanan

This invention relates to carbapenem compounds of the following formula: wherein A, Z, X, R, and Rare as described herein, as well as stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection.

Substituted carbapenems for the treatment of bacterial infections

Described herein are compounds and their use in the treatment of infections. The compound of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, solvates, pharmaceutically acceptable salts and pharmaceutical compositions described herein are also useful as &#x3b2;-lactamase inhibitors, which restore or enhance the antibiotic spectrum of a suitable antibiotic agent. The compounds of formula (I) act as inhibitors of &#x3b2;-lactamases. These compounds restore/potentiate the activities of &#x3b2;-lactam antibiotics against carbapenemases. These compounds find use in diagnostic method for detecting &#x3b2;-lactamases. Formula (I) 

Compounds and their use

Pyrimidine compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof, are useful are useful as PDE4 inhibitors and are useful for treating PDE4 mediated diseases and in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; ARDS; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever. 

Pyrimidine compounds and their uses

Compounds of the formula (I), their derivatives, analogs, tautomeric forms, regioisomers, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, N-oxides, metabolites and prodrugs thereof. These compounds are phosphodiesterase type 4 (PDE4) inhibitors. They are useful in the treatment of a variety of allergic or inflammatory diseases including asthma, COPD, chronic bronchitis, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, vernal conjuctivitis, psoriasis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, uveitis, NASH and lupus.

Heterocyclic compounds as phosphodiesterase inhibitors

Described are novel compounds of the Formula (I), their derivatives, analogs, tautomeric forms, regioisomers, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are effective in lowering blood glucose, serum insulin, free fatty acids, cholesterol, triglyceride levels; treatment of obesity, inflammation, autoimmune diseases such as multiple sclerosis, rheumatoid arthritis; treatment and/or prophylaxis of type II diabetes. These compounds are more particularly dipeptidyl peptidase (DPP IV) inhibitors. 

Dipeptidyl peptidase IV inhibitors

Described are novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; ARDS; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever. More particularly these compounds are useful as PDE4 inhibitors and are useful for treating PDE4 mediated diseases. 

Growing community of inventors

Chennai, India

Gopalan Balasubramanian